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Theaimofthestudywastodeterminethecorrelationbe-
tween the expression of tissue factor (TF) and the receptor
foradvancedglycationendproducts(RAGEs)andvascular
complications in patients with longstanding uncontrolled
type 2 diabetes (T2D). TF and RAGE mRNAs as well as
TF antigen and activity were investigated in 21 T2D pa-
tients with and without vascular complications. mRNA ex-
pression was assessed by reverse transcriptase–polymerase
chain reaction (RT-PCR) in nonstimulated and advanced
glycation end product (AGE) albumin–stimulated periph-
eral blood mononuclear cells (PBMCs). TF antigen expres-
sion was determined by enzyme-linked immunosorbent as-
say (ELISA) and TF activity by a modiﬁed prothrombin
time assay. Basal RAGE mRNA expression was 0.2 ± 0.06
inpatientswithcomplicationsand0.05±0.06patientswith-
outcomplications(P=.004).Stimulationdidnotcauseany
furtherincreaseineithergroup.TFmRNAwas0.58±0.29
in patients with complications and 0.21 ± 0.18 in patients
without complications (P = .003). Stimulation resulted in
a nonsigniﬁcant increase in both groups. Basal TF activity
(U/106 PBMCs) was 18.4 ± 13.2 in patients with complica-
tions and 6.96 ± 5.2 in patients without complications (P=
.003). It increased 3-fold in both groups after stimulation
(P = .001). TF antigen (pg/106 PBMCs) was 33.7 ± 28.6 in
patients with complications, 10.4 ± 7.8 in patients without
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complications (P = .02). Stimulation tripled TF antigen in
both groups of patients (P = .001). The RAGE/TF axis is
up-regulatedinT2Dpatientswithvascularcomplicationsas
compared to patients without complications. This suggests
a role for this axis in the pathogenesis of vascular compli-
cations in T2D.
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There is increasing evidence that in addition to hyper-
glycemia,otherfactorssuchasadvancedglycationendproducts
(AGEs) and their receptors may be related to the development
of these complications. Kilhovd and colleagues demonstrated
that in comparison to controls without diabetes mellitus, AGE
is elevated in serum of patients with type 2 diabetes (T2D)
suffering from ischemic heart disease [1]. AGE deposits were
found in mesangial cells from patients with diabetic nephropa-
thy, and retinal M¨ uller cells from patients with proliferative
diabetic retinopathy [2, 3]. More so, receptor-facilitated cellu-
lar uptake of AGEs induces proliferation of endothelial cells
and migration of smooth muscle cells in atherosclerotic le-
sions [4]. The receptor for AGEs, RAGE, is the most widely
researched member of a family of 5 different receptors [5]. It
has been detected in cells involved in diabetic complications,
such as monocytes, macrophages, and endothelial cells. It was
also found in macro- and microvascular lesions, including the
aorta, the coronary arteries, and leg arteries, as well as in the
retina and glomeruli [6–10]. Moreover, infusion of a truncated
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form of RAGE into diabetic mice with accelerated atheroscle-
rosis reduced AGE uptake into mesangial cells and prevented
neovascularization [11–14]. The exact intracellular molecular
mechanism of AGE induced macro- and microvascular dam-
age is still unclear, but could be linked to AGE-induced tis-
sue factor (TF) activation, as demonstrated by Bierhaus and
colleagues [15]. Incubation of cultured endothelial cells with
AGEs induced transcription of TF mRNA and protein expres-
sion mediated by the p38 mitogen-activated protein kinase
and consecutively the nuclear transcription factor NF-kappa
B, which activated the RAGE gene [15–17]. TF is a procoagu-
lant glycolipoprotein that resides in the cellular membranes of
monocytes, macrophages, and endothelial cells [18]. It is the
main activator of the coagulation system and has been associ-
ated with the development of diabetic vascular complications
[19]. Increased plasma TF activity, most probably generated
by monocytes and endothelial cells, was found in patients with
type1diabetessufferingfromnephropathy[20].Foamymono-
cytes and macrophages accumulate in subendothelial cells at
an early stage of the development of vascular atheroma and
contain large amounts of TF [21]. The existence of ﬁbrin,
platelets, and thrombin in atheromas indicates that TF from
monocytes-macrophages activates locally the coagulation sys-
tem. Moreover, thrombin, generated by TF, has a mitogenic
effect and causes migration and proliferation of ﬁbroblasts in
atheromas[22].Thus,itappearsthattheinteractionbetweenthe
AGE-RAGE system and TF in monocytes plays a signiﬁcant
role in the development of vascular complications in diabetes
mellitus.
TABLE 1
Demographic and clinical characteristics of studied patients
Complications No complications Signiﬁcance
Number of patients (m/f) 11 (6/5) 10 (7/3) n.s.
Duration DM (years) 22 ± 82 8 ± 9 n.s.
Age 59 ± 86 2 ± 13 n.s.
BMI 27.8 ± 3.5 27.2 ± 3.2 n.s.
CIHD 9/11 0/10
CVA 4/11 0/10
PVD 4/11 0/10
HbA1C (%)* 9.4 ± 1.8 8.7 ± 1.6 n.s.
LDL (mg%) 103 ± 22 112 ± 15 n.s.
TG (mg%) 135 ± 80 108 ± 57 n.s.
HDL (mg%) 53 ± 12 58 ± 13 n.s.
Hypertension 8/11 3/10 n.s.
Smokers 1/11 1/10 n.s.
Statin treatment 5/11 2/10 n.s.
Insulin treatment 5/11 6/10 n.s.
∗Normal value <6.4%.
Based on these data, we studied the capacity of peripheral
mononuclear blood cells (PBMCs) from patients with poorly
controlled, longstanding T2D, with and without complications,
to express TF/RAGE before and after stimulation with AGEs.
Our ﬁndings indicate that TF mRNA and protein expression, as
well as expression of RAGE mRNA, are increased in patients
suffering from vascular complications.
PATIENTS AND METHODS
Patients
Clinicalanddemographiccharacteristicsofpatientsarepre-
sentedinTable1.Twenty-onepatients(13malesand8females,
age range 41 to 82 years) with longstanding uncontrolled T2D
(>20 years; hemoglobin A1C (HbA1C) > 8% on repeated de-
terminations, upper normal limit 6.4%) were recruited for the
study. Eleven patients suffered from microvascular complica-
tions deﬁned as diabetic retinopathy and nephropathy. Ten of
thesepatientsalsohadatleastonemacrovascularcomplication,
i.e.,chronicischemicheartdisease,provenbycoronaryangiog-
raphy or coronary bypass graft surgery. Patients were excluded
if they suffered from uncontrolled hypertension (>130/80 mm
Hg) or if their cholesterol and triglyceride levels exceeded the
recommendations of the American Diabetes Association [23].
An entire medical history was obtained and all patients un-
derwent a complete physical examination. Microvascular com-
plications were excluded by a normal fundoscopy, urinary mi-
croalbuminexcretion<30mg/24hin2repeateddeterminations
or urinary microalbumin (mg)/creatinine (mg) ratio <0.02, andRAGE, TF, AND DIABETIC VASCULAR COMPLICATIONS 165
the absence of symptomatic peripheral neuropathy. Macrovas-
cular disease was considered to be unlikely in patients without
microvascular disease in the presence of a normal physical ex-
amination, a normal electrocardiogram, and a negative history
of coronary artery disease, stroke, or peripheral vascular dis-
ease. The local Helsinki committee approved this study and
informed consent was obtained from all patients according to
the regulations.
Isolation and Stimulation of PBMCs with AGE
Albumin
Twenty milliliter of peripheral blood was collected from an
antecubital vein into vacutainers containing EDTA. PBMCs
were separated over a Ficoll-Hypaque gradient (Pharmacia),
washed, and resuspended in RPMI (Rhenium) containing 10%
fetal calf serum and L-glutamine (Biological Industries, Beth
HaEmek, Israel). Based on reports by other investigators who
testedtheeffectofAGEsonendothelialcells,AGEalbuminand
human serum albumin were purchased from Sigma (substitu-
tion 2.7 moles hexose/mole protein) and incubated according
to their published “peak effect” of 12 to 24 hours [15]. Based
on preliminary dose-response studies with different glycated
human serum albumin concentrations (5 µg/mL AGE albumin
did not stimulate TF activity and 200 µg/mL AGE albumin
did not increase TF activity any further than stimulation with
50 µg/mL), 2 × 106 PBMCs per vial, equalized per monocyte
counts, were incubated for 2 and 18 hours in endotoxin-free
medium containing 50 µg/mL glycated human serum albumin
or control medium containing 50 µg/mL human serum albu-
min. Exposure of 2 hours did not induce a detectable increase
in TF or RAGE mRNA below the assay detection limit. After
incubation, PBMCs were washed twice in phosphate-buffered
saline (PBS), separated into 2 vials for determination of TF
activity and mRNA extraction, and frozen at −70◦C.
Determination of Tissue Factor Activity
Frozencellswerethawedat37◦C,resuspendedin1mLPBS,
pH7.35,andsonicatedwithultrasonicvibratorfor60secondsin
an ice bath. TF activity was measured by a modiﬁed prothrom-
bin time assay [24]: Pooled anticoagulated plasma, 0.1 mL,
from at least 10 normal donors was incubated with 0.1 mL cell
suspension at 37◦C for 1 minute, 0.1 mL of 0.025 M CaCl2 was
added, and clotting time was recorded. Each sample was run
in duplicate. TF activity was expressed in units per 106cells,
calculated from standard curves of the logarithm of the activ-
ity of serial dilutions of standard TF. Dilutions of 1:1024 TF
(170 seconds) and 1:16 (32 seconds) were equal to 1 and 64 U,
respectively.
Determination of Tissue Factor Antigen
TF antigen was measured with the Imubid TF ELISA
KIT (American Diagnostica, Greenwich, CT) according to the
manufacturer’s recommendations and expressed in picogram
per 106 PBMCs. TF activity and antigen were also calcu-
lated per milligram of protein cell lysate: the results were
similar.
Isolation of RNA
PBMCs were lysed in TRI reagent (Sigma) according to the
manufacturer’sinstructions.RNAwasresuspendedin10µLof
DEPC water. Typically 20 to 50 µg of total RNA was extracted
from 20 mL of peripheral blood.
mRNA Expression of TF and RAGE
Reverse transcription–polymerase chain reaction (RT-PCR)
wasperformedwithcommerciallyavailablekits(Epicentreand
Sigma) according to the manufacturer’s instructions. Primers
for transcription factor, RAGE, and glyceraldehyde-phosphate
dehydrogenase (GAPDH) were designed according to pre-
vious reports [15, 25]. The coding strand primer for tissue
factor corresponds to positions 759 to 784 of the published
DNA sequence, the noncoding strand to positions 1016 to
1041. The coding strand primer for GAPDH corresponds
to positions 562 to 582, the noncoding strand to positions 807
to 827. The coding strand primer for RAGE corresponds to po-
sitions 29 to 54, the noncoding strand to positions 481 to 509.
PCR reactions were performed with TAQ polymerase (MBI,
Fermentas): 94◦C 3 minutes (hot start), 94◦C 1 minute, 60◦C
30 seconds, 72◦C 1 minute, 40 cycles (optimal ampliﬁcation
rate according to preliminary experiments). RAGE was iden-
tiﬁed by restriction enzyme digestion with BAMH1, revealing
2 DNA fragments of 251 and 188 base pairs, respectively. Ten-
microliter aliquots of the PCR reactions were analyzed on a
1.5%agarosegelcontainingethidiumbromide.Forsemiquanti-
tativeRT-PCR,thesignalsobtainedfortissuefactorandRAGE
werecomparedbydensitometrytotheintensityoftheampliﬁed
housekeeping gene GAPDH and expressed as optical density
(OD) ratio ± SD.
Statistics
Clinical and demographic characteristics of patients were
evaluatedbyPearsonchisquareandFisherexacttests(1-tailand
2-tail). Analysis of variance (ANOVA) with repeated measures
wasusedforevaluationofthedata.Thesquareroottransforma-
tion was used for those variables that did not have a Gaussian
distribution to analyze the effect of stimulation and interaction
between the groups.166 A. E. BUCHS ET AL.
TABLE 2a
Expression of TF and RAGE mRNA in type 2 diabetes patients with and without complications
TF RNA OD ratio RAGE RNA OD ratio
Basal Stimulation N Basal Stimulation Nc
Complications 0.58 ± 0.29 0.79 ± 0.21 11 0.2 ± 0.06 0.2 ± 0.09 10
No complications 0.21 ± 0.18 0.46 ± 0.32 10 0.04 ± 0.06 0.13 ± 0.13 10
P value .003a n.s.b .01a n.s.b
Note. Nonstimulated and AGE-stimulated PBMCs were analyzed. mRNA expression was determined by RT-PCR, quantiﬁed by densitometry,
and expressed as the ratio of gene/GAPDH mean ± SD. P values: aDifference between the basal, nonstimulated values in patients with and
without complications. bComparison of the response to stimulation of both groups.cComparison between nonstimulated and stimulated values
was available for 8 patients within each group.
RESULTS
TF mRNA Expression
Basal and stimulated TF mRNA expression was determined
inPBMCsfrom11patientswithand10patientswithoutmacro-
and microvascular complications. Overall, mRNA TF expres-
sion was higher in the studied patients suffering from diabetes
than in controls without diabetes (data not shown). As demon-
strated in Table 2a, TF mRNA was signiﬁcantly higher in the
complicated than noncomplicated patients: 0.58 ± 0.29 and
0.21±0.18,respectively(P = .003).Inordertoinvestigatethe
effect of glycated albumin on TF mRNA expression, PBMCs
were incubated for 18 hours in the presence of 50 µg/mL
AGE albumin. This caused a nonsigniﬁcant increase in TF
mRNA expression in both groups: 0.79 ± 0.21 and 0.46 ±
0.32, respectively.
These data show that TF mRNA expression is increased in
patients with T2D and vascular complications.
TF Antigen and Activity
To determine the relevance of increased TF mRNA ex-
pression in complicated patients, we examined the expres-
sion of the TF antigen and its functional activity (Table 2b).
Basal nonstimulated TF protein expression was 33.7 ± 28.6
pg/106 PBMCs and 10.4 ± 7.8 pg/106 PBMCs in patients
TABLE 2b
Expression and activity of TF in type 2 diabetes patients with and without complications
TF activity U/106 PBMCs TF protein pg/106 PBMCs
Basal Stimulation N Basal Stimulation Nc
Complications 18.4 ± 13 56.4 ± 26.2 10 33.7 ± 28.6 108.4 ± 39 8
No complications 6.96 ± 5.2 19.4 ± 7.62 6 10.4 ± 7.8 45.5 ± 33.3 5
P value .003a .001b .02a .001b
Note. Nonstimulated and AGE-stimulated PBMCs were analyzed. TF activity was determined by a modiﬁed prothrombin time assay and
expressedinarbitraryunits/106PMBCs±SD.TFproteinwasdeterminedbyELISA.Pvalues: aDifferencebetweenthebasal,nonstimulated
values in patients with and without complications. bComparison of the response to stimulation of both groups.
with and without complications, respectively, P = .02. In-
cubation with AGE albumin (50 µg/mL) increased TF anti-
gen approximately 3-fold in both groups with diabetes to
108.4 ± 39 pg/106 PBMCs and 45.5 ± 33.3 pg/106 PBMCs in
the complicated and the noncomplicated groups, respectively.
This stimulatory effect on TF antigen was highly signiﬁcant
(P <. 001).
As shown in Table 2b, basal TF activity was signiﬁcantly
higher in the patients with complications: 18.4 ± 13 U/106
PBMCs and 6.96 ± 5.2 U/106 PBMCs, respectively (P =
.003). Incubation with 50 µg/mL AGE albumin resulted in a
3-foldincreaseinTFactivityof56.4±26.2U/106 PBMCsand
19.4 ± 7.6 U/106 PBMCs in groups with and without compli-
cations, respectively. The effect of stimulation was signiﬁcant
in both groups (P = .001).
These data demonstrate that, in comparison to diabetic
individuals without complications, both TF antigen expression
and activity are markedly increased in patients with diabetic
complications.
RAGE mRNA Expression
We examined basal and stimulated RAGE mRNA expres-
sion to determine whether the increased TF expression and ac-
tivityisduetoAGE-mediatedactivationofRAGE.AsshowninRAGE, TF, AND DIABETIC VASCULAR COMPLICATIONS 167
FIGURE 1
Representative agarose gels demonstrating TF and RAGE
expression nonstimulated and AGE-stimulated PBMCs were
analyzed. PCR products were analyzed on ethidium
bromide–stained 1.5% agarose gels. DNA marker, left lane
(M), fragment sizes (arrows): GAPDH: 257 bP; TF: 245 bP;
RAGE: 480 bP. Lanes 1 to 3: no stimulation; lanes 4 to 6
stimulation with AGE 50 (µg/mL). Top gel: A typical gel
from a patient without complications. GAPDH: lanes 1 and 4;
TF: lanes 2 and 5; RAGE: lanes 3 and 6. Bottom gel: A typical
gel from a patient with complications. GAPDH: lanes 1 and 4;
TF: lanes 2 and 6; RAGE: lanes 3 and 5.
Figure 1 and Table 2a, the mean nonstimulated RAGE expres-
sion were 0.20 ± 0.06 and 0.04 ± 0.06 in the complicated and
the noncomplicated group, respectively, P <. 01. Stimulation
with AGE albumin at 50 µg/mL failed to cause a signiﬁcant
increase in RAGE mRNA expression in either group.
These data show that mRNA expression is increased in pa-
tients with complications in comparison to patients without
complications and cannot be further increased by exposure to
AGE albumin.
DISCUSSION
We demonstrate here that nonstimulated and AGE-
stimulated TF mRNA and protein expression and TF protein
activity are signiﬁcantly increased in PBMCs from T2D pa-
tientswithcomplicationsascomparedtopatientswithoutcom-
plications. mRNA expression of RAGE is also markedly in-
creased in the former group. To the best of our knowledge,
this is the ﬁrst report correlating existing diabetic complica-
tions to the expression of TF and RAGE in PBMCs from pa-
tients with diabetes. So far, in clinical settings, TF and RAGE
expression has only been examined separately and indepen-
dently. Ichikawa and colleagues reported increased TF protein
expression in monocytes from patients suffering from diabetic
nephropathy [26]. Reverter and colleagues noted that serum
from patients with type 1 diabetes induced higher TF secretion
in normal mononuclear cells than control serum from healthy
controls [27]. Serum from patients who developed retinopathy
upon long-term follow-up induced TF expression to an espe-
cially high level [28]. Jinnouchi and Bierhaus and their col-
leagues reported RAGE-dependent induction of TF in cultured
endothelial cells and accumulation of AGEs in macrophages
and foam cells of atheromatous lesions [15, 20]. We there-
fore investigated whether AGEs also induce TF expression in
PBMCs from diabetic patients. Our data further support the
role of an overexpressed RAGE/TF cascade in the pathogene-
sisofvascularcomplicationsindiabetes.HowtheincreasedTF
expression/activity in diabetic patients underlies their compli-
cationsisnotclear.IncreasedTF,asevidentinourpatientswith
complications, may be a facilitating factor for vascular compli-
cations by contributing to the hypercoagulable state of diabetes
[29]. It is of interest that TF is increased in diabetic individu-
als without complications in comparison with normal controls,
the level of TF of whom we have repeatedly veriﬁed to be be-
low the assay detection limit. This raises the possibility of a
threshold necessary for the development of vascular complica-
tionsinT2Dpatients.RAGEmRNAexpressionwasalsohigher
in patients with complications than in those without. Because
activated RAGE is a known mediator of TF expression, this ac-
centuatestheimportanceofincreasedTFexpression/activityin
thesepatients.Ifthisisthecase,TFmRNAexpressionorprotein
activity could serve as a prognostic marker to deﬁne patients
who are prone to develop vascular complications. Long-term
follow-up studies may allow us to determine whether the asso-
ciationbetweenTF/RAGEexpressioniscoincidentalorcausal.
In contrast to TF, we could not demonstrate a further AGE-
stimulatedincreaseinRAGEmRNAexpressioninpatientswith
complications. Several mechanisms may explain this discrep-
ancy: (1) We examined the expression of only 1 out of 5 known
AGE receptors. The stimulated increase in TF in our patients
may be mediated by AGE binding to a different AGE recep-
tor, such as the macrophage scavenger receptor as previously
reported in the murine macrophage cell line RAW 264.7 [30,
31]. This hypothesis is supported by He and colleagues, who,
despitehighserumAGElevels,failedtodetectup-regulationof
RAGE mRNA or its protein in PBMCs from diabetic patients
with macrovascular complications [32]. (2) Increased levels of
HbA1C as seen in our patients reﬂect elevated concentration of
AGE in their serum. This may have caused maximal in vivo168 A. E. BUCHS ET AL.
stimulation of RAGE, preventing further increase by addition
ofAGEsinvitro.(3)mRNAstabilityisakeyfactordetermining
its levels as shown in endotoxin stimulated mononuclear cells
[33]. Thus, it is conceivable that AGEs regulate RAGE mRNA
levels in diabetic PBMCs by modifying RAGE stability rather
than increasing its synthesis de novo.
To the best of our knowledge, it has not been shown that
vascular complications in diabetes are more prevalent or severe
in a particular gender. All of our female patients within the
study were postmenopausal and not on hormonal replacement
therapy. We decided, therefore, not to study male and female
patients separately but cannot exclude that this is a topic that
will have to be studied in the future. Furthermore, we cannot
excludethatsomeofthe“noncomplicated”patientsincludedin
our study in fact do have minor asymptomatic macrovascular
disease. More sophisticated and invasive tests are required to
exclude these conditions. Based on previous reports, however,
we considered it unlikely that the included patients suffer from
signiﬁcant cardiovascular disease in the absence of increased
microalbuminuria [34]. Hypertension and hyperlipidemia are
acceptedriskfactorsformacrovasculardiseaseindiabetes[35].
This is of a particular importance in as much as both hyper-
tension and treatment with statins were more prevalent in the
complication group. In addition, more patients with complica-
tions took ACE inhibitors or angiotensin II (ATII) antagonists
thaninthegroupwithoutcomplications.However,itisunlikely
that these differences explain our results because blood pres-
sure was well controlled in all patients and lipid levels were
similar in both groups irrespective of drug treatment. Further-
more,ACEinhibitorsandstatinsreduceratherthanincreaseTF
expression in monocytes [36]. We believe, therefore, that these
minor differences in risk stratiﬁcation and drug regimens did
not inﬂuence our data.
In conclusion, our data demonstrate that diabetic complica-
tions are associated with enhanced TF mRNA expression and
protein activity as well as increased RAGE mRNA expression.
In addition to tight blood glucose control, the RAGE/TF axis
could serve as potential treatment target for the prevention of
diabetic complications.
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